FDA Approves First Drug for Moderate and Severe Eczema Cases

U. S. FDA approved Dupixent injection to treat adults with moderate-to-severe eczema. Dupixent is intended for patients whose eczema is not controlled adequately by topical therapies, or those for whom topical therapies are not advisable.

FDA Approves First Drug for Moderate and Severe Eczema Cases

Highlights

  • Dupixent is an antibody that is injected just under the skin.
  • Injection will have initial list price of USD 37000 per year, as per sanofi SA and Regeneron Pharmaceuticals.
  • In two large tests of the drug, one-third to two-thirds of patients achieved clear or nearly clear skin.
  • Eczema treatments have generally been limited to topical medications
    • Steroid creams
    • Moisturizers
    • Ultraviolet light
  • Dupixents active ingredient is an antibody that binds to a protein that causes inflammation.

About FDA

  • Is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.
  • Is responsible for protecting and promoting public health through the control and supervision of food safety.
  • Is led by the Commissioner of Food and Drugs, appointed by the President with the advice and consent of the Senate.
  • Its headquarters in unincorporated White Oak, Maryland.

Regulatory programs:

Regulatory Programs

Examrace Team at Aug 21, 2021